Result: Risk Minimisation Materials for medicines starting with the letter I

Ibandronic acid

Accord-UK Ltd

Ibandronic Acid - Patient Reminder Card

This reminder card contains important safety information that you need to be aware of before and during treatment with Ibandronic acid Actavis 3mg Solution for Injection for treatment of osteoporosis in postmenopausal women at increased risk of fracture

Iclusig

Incyte Biosciences UK Ltd

Iclusig (ponatinib): Important Safety Information for Healthcare Professionals

As part of the terms of the Marketing Authorisation for Iclusig, Incyte Biosciences (UK) Ltd are required to ensure that all Healthcare Professionals who are likely to treat patients with ponatinib are provided with risk minimisation materials. This document contains key information to help identify patients eligible for therapy, understand how ponatinib should be used safely, the risks for patients and the important adverse reactions for which monitoring and dose adjustment are recommended (pancreatitis, increased amylase and lipase levels, myelosuppression, liver function test abnormalities, haemorrhage, cardiac failure/left ventricular dysfunction, arterial occlusion and venous thromboembolism events and hypertension). If you require further information about ponatinib, please consult the SmPC for Iclusig available on www.ema.europa.eu or contact Incyte Biosciences (UK) Ltd on the EU universal free telephone number 00800 00027423.

For Healthcare Professionals

Ilaris

Novartis Pharmaceuticals UK Ltd

Ilaris - Important information for patients with Gouty Arthritis

Patient alert card listing important information to consider before and during treatment with canakinumab for patients with Gouty Arthritis

Ilaris - Important information for patients with Period Fever Syndromes

Patient alert card listing important information to consider before and during treatment with canakinumab for patients with Periodic Fever Syndromes CAPS, TRAPS, HIDS/MKD or FMF

Ilaris - Important information for the patient with Still's Disease (including Adult Onset Still's Disease) and Systemic Juvenile Idiopathic Arthritis

Patient alert card listing important information to consider before and during treatment with canakinumab for patients with Still's Disease (including Adult Onset Still's Disease) and Systemic Juvenile Idiopathic Arthritis

Iluvien

Alimera Sciences Limited

ILUVIEN® Administration Guide

Guidance on the administration technique and details of important adverse events

For Healthcare Professionals

Imlygic

Amgen Ltd

IMLYGIC Information for Patients and Close Contacts

This brochure contains important safety information you should know before and during IMLYGIC treatment. Please read this information carefully before and after each treatment. Please also read the IMLYGIC Package Leaflet. To request a copy of this guide, please contact Amgen Medical Information on +44 (0) 1223 436441

IMLYGIC Patient Alert Card

This IMLYGIC patient alert card includes contact details of the IMLYGIC prescriber, treatment start date, IMLYGIC batch number and information on the potential development of herpetic lesions and the importance of reporting ADRs. To request a copy of the patient card, please contact Amgen Medical Information on +44 (0) 1223 436441

IMLYGIC Physician's Brochure

This educational brochure contains important information regarding the risks of transmission and herpetic complications, and safe use and handling of IMLYGIC.This brochure does not contain a comprehensive description of the risks associated with IMLYGIC. Please read the current Summary of Product Characteristics (SmPC) for IMLYGIC. To request a copy of the brochure, please contact Amgen Medical Information on +44 (0) 1223 436441

For Healthcare Professionals

Imraldi

Biogen Biosimilars

Imraldi Patient Alert Card

This card contains select important safety information that patients need to know before and during treatment with Imraldi.

Imraldi Safety Brochure

The purpose of this safety monograph is to inform physicians and other HCPs about the key safety risks associated with the use of TNF antagonists such as adalimumab (IMRALDI®), and to help HCPs in screening and monitoring patients appropriately while they are receiving TNF antagonist therapy.

For Healthcare Professionals

Imraldi TB Brochure

TUBERCULOSIS (TB) SCREENING BEFORE INITIATING ANTI-TNF THERAPY - A RESOURCE GUIDE FOR HCPs

For Healthcare Professionals

Increlex

Ipsen Ltd

Increlex Dosing Guide

How to use Increlex in the treatment of severe primary IGF-1 deficiency

For Healthcare Professionals

Increlex Hypoglycaemia Leaflet

Information for parents, caregivers, or for patients about hypoglycaemia and what to do if it occurs

Increlex Instructions for Use

This leaflet is a quick reference guide to preparing and injecting Increlex®

Increlex Patient Leaflet

Patient educational information about severe primary IGF-1 deficiency and how Increlex® can help

Increlex Physician Leaflet

Physician information about Increlex®

For Healthcare Professionals

Inflectra

Pfizer Limited

Inflectra Patient Alert Card

The Alert Card contains important safety information that you need to be aware of before and during treatment with Inflectra.

Inflectra Patient Safety Folder

The guidance provides important information on the risks of treatment with Inflectra.

For Healthcare Professionals

Inflectra Patient Screening Sheet

Provides guidance to HCP involved in screening and selection of patients to be treated with Inflectra.

For Healthcare Professionals

Instanyl

Takeda UK Ltd

Instanyl (fentanyl citrate) Single Dose Patient Guide

To be provided to patients receiving treatment with Instanyl by a HCP

Irbesartan+Hydrochlorothiazide

Aurobindo Pharma - Milpharm Ltd.

Irbesartan/HCTZ- HCP letter- Hydrochlorothiazide and the risk of non-melanoma skin cancer

The prescriber should inform the patients taking hydrochlorothiazide (HCTZ) containing medicines of the risk of non-melanoma skin cancer. Patients should be advised to limit the exposure to sunlight and UV rays and use adequate protection when exposed to sunlight and UV rays to minimise the risk of skin cancer

For Healthcare Professionals

Isotretinoin

Generics UK T/A Mylan

Isotretinoin Checklist for Prescribing to Female Patients

Pregnancy Prevention Programme, Checklist for Prescribing to Female Patients

For Healthcare Professionals

Isotretinoin Patient Reminder Card

This material is provided by Mylan as a licence requirement for this medicine and forms part of the Pregnancy Prevention Programme.

Isotretinoin Pharmacist Checklist

This material is provided by Mylan as a licence requirement for this medicine and forms part of the Pregnancy Prevention Programme.

For Healthcare Professionals

Isotretinoin Pharmacist's Guide

Pregnancy Prevention Programme, Pharmacist's Guide to Dispensing Isotretinoin

For Healthcare Professionals

Isotretinoin Prescriber Checklist

This material is provided by Mylan as a licence requirement for this medicine and forms part of the Pregnancy Prevention Programme.

For Healthcare Professionals

Ranbaxy (UK) Limited a Sun Pharmaceutical Company

Patient Reminder Card

Patient Reminder Card for Isotretinoin - Important information to know when taking isotretinoin and what you must do.

Pharmacist checklist

Guidance for dispensing Oral Isotretinoin. Isotretinoin is strictly contraindicated during pregnancy and in women of childbearing potential, unless all conditions in the Isotretinoin Pregnancy Prevention Programme are fulfilled

For Healthcare Professionals

Prescriber checklist

Acknowledgement Form for Prescribing Isotretinoin to Female Patients. The potential for pregnancy must be assessed for all female patients prescribed Isotretinoin.

For Healthcare Professionals

Alliance Pharmaceuticals

Patient Reminder Card for Isotretinoin

This material is provided by Alliance Pharmaceuticals Ltd as a licence requirement for this medicine and forms part of the Pregnancy Prevention Programme. This booklet should be given to patients who have been prescribed Isotretinoin and it describes some of the important facts about Isotretinoin that you need to be aware of

Pharmacist’s Guide to Dispensing Isotretinoin

This material is provided by Alliance Pharmaceuticals Ltd as a licence requirement for this medicine and forms part of the Pregnancy Prevention Programme. This booklet is intended for pharmacists who are involved with dispensing Isotretinoin and it provides a guide to dispensing Isotretinoin in accordance with the Pregnancy Prevention Programme

For Healthcare Professionals

Prescriber Checklist Acknowledgement Form for Prescribing to Female Patients

This material is provided by Alliance Pharmaceuticals Ltd as a licence requirement for this medicine and forms part of the Pregnancy Prevention Programme. This checklist should be completed by the prescriber prior to initiating therapy with Isotretinoin

For Healthcare Professionals

Izinova

Ipsen Ltd

Izinova Uk RMM Patient Leaflet

Patient leaflet advising on dosing before a bowel cleansing procedure. Version 2 approved Oct 2016.

Izinova UK RMM Physician Leaflet

Physician leaflet advising on dosing, contraindications and precautions. Version 2 dated Oct 2016.

For Healthcare Professionals